THIS DEAL, NO DEAL, OR MORE TIME? A CRUCIAL BREXIT WEEK

THIS DEAL, NO DEAL, OR MORE TIME? A CRUCIAL BREXIT WEEK

The economic future of the UK – and the political future of PM Theresa May – (once again!) hang in the balance this week as British lawmakers take up three big Brexit votes.


Tuesday – "Take it or leave it": Today Parliament will decide whether to approve May's existing Brexit deal – yes, essentially the same one that lawmakers crushed by a historic margin of 230 votes back in January. The one that ran aground in part because it would allow the UK to stay closely aligned with the EU until a solution can be found to the Irish border question. No one we know thinks the deal will pass today, but the margin of defeat matters. If it's huge, that would spell the end of May's deal altogether and might even push her towards resigning. A narrower loss, meanwhile, would at least leave open the possibility that she could go back to Brussels and say "look, we're close, work with me" though the EU seems disinclined to allow that. May reportedly secured some minor concessions from the EU late yesterday evening, but it's not clear if those are enough for her to claim real progress towards a better deal.

Wednesday – "Deal or no deal?": If the deal vote is a blowout loss, then May will ask Parliament for a second vote on whether it can live with so-called "no-deal Brexit", one in which the UK hurtles out of the EU with no economic transition agreements at all. Given how economically disruptive that would be, odds are most lawmakers will vote against it.

Thursday – "Can I get a minute": That, in turn, would lead to a third vote: whether to extend the current "Brexit" deadline of 29 March, giving officials more time to sort out the issue.

We'll be watching this story all week….

Vaccines are the best hope to end the COVID-19 pandemic. But rich countries are hogging most of the doses, with more than 83 percent of shots administered to date having gone to residents in high- and upper-middle-income countries. Most poor countries will have to wait years to achieve widespread vaccination, according to one study.

To address this inequity some stakeholders are pushing hard for waivers to intellectual-property (IP) rights through World Trade Organization trade rules so that manufacturers in poorer countries can make their own vaccines locally. India and South Africa have been leading the charge, which would essentially mean that deep-pocketed pharma companies like New York-based Pfizer, for instance, would have to hand over the keys to the kingdom, allowing local companies in New Delhi and Johannesberg to make generic versions of their vaccines.

Unsurprisingly, the debate has gotten fiery, with passionate arguments emerging both for and against.

More Show less

Russian president Vladimir Putin on Wednesday threatened an "asymmetrical, rapid, and harsh" response for anyone that dares to cross a "red line" with Russia.

What's the red line? Putin says he'll decide on a case-by-case basis. And the cases at the moment are growing: the US has sanctioned Russia over cyber crimes; Putin critic Alexei Navalny is near death in a Russian prison; the Czechs say Russia blew up a Czech munitions depot; and as many as 120,000 Russian troops are reported to be massing along Russia's border with Eastern Ukraine.

Which is to say: there's potentially a Sol Lewitt's-worth of red lines to ponder now.

Europe has been hit by a green wave in recent years. Green parties in countries as varied as Germany, Belgium, France, Ireland, Finland, and Sweden have made sizable electoral gains, with some now sitting in national governments.

The Green phenomenon seems to be gaining yet more momentum in the lead up to some crucial European elections (Germany, France) in the months ahead. What explains the green shift, and where might this trend be headed?

More Show less

More than 930 million doses of COVID-19 vaccine have already been administered globally, and another 1 billion more are expected to be manufactured by the end of May. Most of the manufacturing is concentrated in a small group of countries. While some — like China, for instance — are exporting roughly half of the shots they make, others — mainly the US — are keeping most of the supply for domestic use. Meanwhile, export controls have been a particularly thorny issue in the European Union and India, where governments have come under intense pressure to stop sending vaccines to other parts of the world amid sluggish rollouts at home. We take a look at what the world's top manufacturers are doing with the vaccines they are producing.

Ian Bremmer explains how a fire on the Cuyahoga River in Cleveland, Ohio, in the summer of 1969, set the conservation movement ablaze in the United States. A TIME Magazine article about the fire led to the Clean Water Act, creation of the EPA, and the first Earth Day—April 22, 1970. Over 50 years later, citizens of the world agree that climate change is a global emergency. But how can nations come together to find solutions that are truly attainable?

Watch the GZERO World episode: Can We Fix the Planet the Same Way We Broke It?

US President Joe Biden's highly anticipated two-day climate summit opens on Thursday, when dozens of world leaders and bigshot CEOs will gather (virtually) to try to save the planet. Above all, the US is looking to showcase the idea that "America is back" on climate change. But will other countries buy it?

More Show less

55: EU governments on Wednesday reached a deal to cut greenhouse gas emissions by 55 percent from 1990 levels by the end of the decade. The commitment is in line with the bloc's broader goal of going carbon-neutral by 2050.

More Show less

Subscribe to GZERO Media's newsletter, Signal

The GZERO World Podcast with Ian Bremmer. Listen now.

GZEROMEDIA

Subscribe to GZERO Media's newsletter: Signal